<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11119-2014029 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Virological and serological predictors of high-grade anal intraepithelial neoplasia (HGAIN) in HIV-infected men who have sex with men (MSM)</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">In this project we will identify biomarkers that predict HGAIN in HIV-infected MSM. Hereto we will use a cohort of 327 hiv positive MSM (H2M study).
The research questions are:
-1- Does a persistent anal high-risk HPV (hr-HPV) infection predict the presence of HGAIN?
-2- Does the HPV-type of a persistent anal hr-HPV infection predict the presence of HGAIN?
-3- Does the HPV viral load of an anal hr-HPV infection predict the presence of HGAIN?
-4- Do L1, E6, or E7 HPV-type specific antibodies predict the presence of HGAIN?
-5- Do HIV viral load, current CD4 count or nadir CD4 count predict the presence of HGAIN?
-6- Is the HPV type in an HGAIN lesion the same as the HPV type of the persistent anal infection in that individual?

The output are scientific publication and data for databases.
The outcomes will be better predictive measures for anal cancer.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Since combination antiretroviral therapy (cART) became available, AIDS mortality among HIV-infected people has decreased substantially. Anal squamous cell cancer (SCC) is a non-AIDS defining malignancy that is now one of the most frequent malignancies among HIV infected. Among HIV-infected men who have sex with men (MSM) its incidence is even higher than that of cervical cancer in unscreened female populations. Like cervical cancer, anal SCC is caused by human papillomavirus (HPV) and pre-cancer stages of anal SCC, i.e. anal intraepithelial neoplasia (AIN), can be detected and treated. Unfortunately anal cytology is not suitable as a screening strategy because of its low sensitivity and specificity regarding high-grade AIN (HGAIN). In this project we will investigate whether a number of other promising biomarkers are predictive for HGAIN, i.e. persistent high-risk HPV infections; HPV anal viral load; and L1, E6, and E7 seropositivity. A cohort of 320 HIV-infected MSM from Amsterdam, who have been examined for HPV during a follow up period of 2 years, will be invited to undergo high resolution anoscopy. Abnormal tissue will be biopsied to make a diagnosis of HGAIN. Subsequently we will examine which of the selected biomarkers predict HGAIN.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">Since combination antiretroviral therapy (cART) became available, AIDS mortality among HIV-infected people has decreased substantially. Anal squamous cell cancer (SCC) is a non-AIDS
defining malignancy that is now one of the most frequent malignancies among HIV infected. Among HIV-infected men who have sex with men (MSM) its incidence is even higher than that of cervical cancer in unscreened female populations.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific community
patients with prestages of anal cancer</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-37099076" role="4" type="80">
   <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-11-30" type="1"></activity-date>
  <activity-date iso-date="2018-06-01" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Virological and serological predictors of high-grade anal intraepithelial neoplasia (HGAIN) in HIV-infected men who have sex with men (MSM) STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2014-11-30"></period-start>
   <period-end iso-date="2018-06-01"></period-end>
   <value currency="EUR" value-date="2014-11-30">220864</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">58898</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">58898</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-03-27"></transaction-date>
   <value currency="EUR" value-date="2016-03-27">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-09-27"></transaction-date>
   <value currency="EUR" value-date="2016-09-27">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-03-26"></transaction-date>
   <value currency="EUR" value-date="2017-03-26">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-03-27"></transaction-date>
   <value currency="EUR" value-date="2017-03-27">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-09-26"></transaction-date>
   <value currency="EUR" value-date="2017-09-26">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-09-27"></transaction-date>
   <value currency="EUR" value-date="2017-09-27">29449</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">44170</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014029, kpl 2636</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">GGD Amsterdam - Dept of Infectious diseases, Research and prevention</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
